Head-to-head evidence
Balcinrenone vs Finerenone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Mineralocorticoid receptor · full Heart Failure pipeline
Balcinrenone
Developed by AstraZeneca
NCT04595370 · Phase 2 · completed
The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.
Next expected readout: April 2027 · NCT06307652 (registry estimate)
Finerenone · Kerendia
Marketed by Bayer and partners
NCT04435626 · Phase 3 · completed
The trial randomized 6,016 participants to finerenone or matching placebo and masked participants, care providers, investigators, and outcome assessors. Its hard clinical primary endpoint was met: finerenone produced fewer cardiovascular death and recurrent heart-failure events than placebo, with a rate ratio of 0.84 (95% CI 0.74–0.95; p=0.0072).
Next expected readout: September 2027 · NCT07830940 (registry estimate)
Chronic Kidney Disease
Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline
Balcinrenone
Developed by AstraZeneca
NCT04595370 · Phase 2 · completed
The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.
Next expected readout: July 2030 · NCT07624305 (registry estimate)
Finerenone · Kerendia
Marketed by Bayer and partners
NCT02540993 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and large, with 5,734 participants randomized nearly equally between finerenone and placebo. Its hard clinical kidney endpoint was met: 504 participants receiving finerenone versus 600 receiving placebo experienced the primary outcome, with a statistically significant hazard ratio of 0.825 (p=0.0014).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Balcinrenone's landscape · Finerenone's landscape